Pharmaceutical controversies and the performative value of uncertainty

Science as Culture

Volumn 18, Issue 2, 2009, Pages 151-164

  McGoey, Linsey ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Capitalized uncertainty; Pharmaceutical controversies; Product liability cases; Strategic ignorance

Indexed keywords

EID: 84861652348     PISSN: 09505431     EISSN: 14701189     Source Type: Journal    
DOI: 10.1080/09505430902885474     Document Type: Article

References (69)

1. Abraham, J., 1994. Distributing the benefit of the doubt:scientists, regulators and drug safety. Science, Technology & Human Values, 19:493–522.
2. Abraham, J., 1995. Science, Politics and the Pharmaceutical Industry, London:University College London Press.
3. Abraham, J., 2002. The pharmaceutical industry as a political player. Lancet, 360 9 November:1498–1501.
4. Abraham, J., and Davis, C., 2006. Testing times:the emergence of the Practolol disaster and its challenge to British drug regulation in the modern period. Social History of Medicine, 19:127–147.
5. Abraham, J., and Sheppard, J., 1999. Complacent and conflicting scientific expertise in British and American drug regulation:clinical risk assessment of Triazolam. Social Studies of Science, 29:803–843.
6. Arnoldi, J., 2004. Derivatives:virtual values and real risks. Theory, Culture and Society, 21 (5):23–42.
7. Avorn, J., 2006. Dangerous deception:hiding the evidence of adverse drug effects. New England Journal of Medicine, 355 23 November:2169–2171.
8. Balmer, B., Science, politics and germ warfare:confessional uncertainty and expert advice. Draft paper presented at Democracy Socialized. August24–28, Cardiff.
9. Beck, U., 1994. “ The reinvention of politics:towards a theory of reflexive modernization ”. In Reflexive Modernization, Edited by:Giddens, A., Beck, U., and Lash, S., Cambridge:Polity Press.
10. Beck, U., 2002. The terrorist threat:world risk society revisited. Theory, Culture and Society, 19:39–55.
11. Berenson, A., 2005. For Merck, Vioxx paper trail won't go away. New York Times, 21 August
12. Berenson, A., Harris, G., Meier, B., and Pollack, A., 2004. Despite warnings, drug giant took long path to Vioxx recall. New York Times, 14 November
13. Best, J., 2007. Why the economy is often the exception to politics as usual. Theory, Culture and Society, 24:87–109.
14. Beunza, D., and Stark, D., 2004. Tools of the trade:the socio-technology of arbitrage in a Wall Street trading room. Industrial and Corporate Change, 13:369–400.
15. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., 2000. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 343:1520–1528.
16. BusinessWeek. 2005. The pain is just beginning:why the Vioxx debacle will hobble Merck for years to come. BusinessWeek, 5 September
17. Coombe, R. J., 2001. “ The demonic place of ‘not there’:trademark rumours in the postindustrial imaginary ”. In Culture, Power, Place:Explorations in Critical Anthropology, Edited by:Gupta, A., and Ferguson, J., Durham, NC and London:Duke University Press.
18. Cooper, M., 2004. On the brink—from mutual deterrence to uncontrollable war. Contretemps, 4, September
19. Cooper, M., 2006. Pre-empting emergence:the biological turn in the war on terror. Theory, Culture and Society, 23:113–135.
20. Cooper, M., 2008. Life as Surplus:Biotechnology and Capitalism in the Neoliberal Era, University of Washington Press.
21. Corrigan, O. P., 2002. A risky business:the detection of adverse drug reactions in clinical trials and post-marketing exercises. Social Science & Medicine, 55:497–507.
22. Culp, D., and Berry, I., 2007. Merck and the Vioxx debacle:deadly loyalty. St. John's Journal of Legal Commentary, 22:1–34.
23. Curfman, G., Morrissey, S., and Drazen, J., 2005. Expression of concern reaffirmed. New England Journal of Medicine, 354:1193
24. Das, V., 1995. Critical Events:An Anthropological Perspective on Contemporary India, Oxford:Oxford University Press.
25. Demeritt, D., 2006. Science studies, climate change, and the prospects for constructivist critique. Economy and Society, 35:453–479.
26. Demortain, D., 2008. From drug crises to regulatory change:the mediation of expertise. Health, Risk and Society, 10 (1):37–51.
27. Douglas, M., and Wildavsky, A., 1983. Risk and Culture:An Essay on the Selection of Technological and Environmental Dangers, Berkeley, CA:University of California Press.
28. Ericson, R., and Doyle, A., 2004. Catastrophe risk, insurance and terrorism. Economy and Society, 33:135–173.
29. Fraser, M., 2006. The ethics of reality and virtual reality:Latour, facts and values. History of the Human Sciences, 19:45–72.
30. FDA. 2007. Merck Wins Vioxx Case in Florida. FDA news Drug Daily Bulletin. October 16 (Volume 4). Available at:http://www.fdanews.com/devicemanufacturing/newsletter/article/print?issueId=10863&articleId=99798
31. FT. 2007. Merck vs Schering. Financial Times, ‘Merger Market’. Available at:http://www.ft.com/cms/s/1/67122922-8235-11dc-8a8f-0000779fd2ac,dwp_uuid=e8477cc4-c820-11db-b0dc-000b5df10621.html (last accessed 24 October 2007)
32. Graham, D. J., 2004. Testimony of David J. Graham, MD, MPH. US Senate, Available at:http://www.senate.gov/~finance/hearings/testimony/2004test/111804dgtest.pdf (last accessed May 2007)
33. Horton, R., 2004a. Depressing research. The Lancet, 363:1335
34. Horton, R., 2004b. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet, 364:1995–1996.
35. Hutter, B., and Power, M., 2005. Organizational Encounters with Risk, Cambridge:Cambridge University Press.
36. Jackson, E., 2006. Medical Law:Text, Cases and Materials, Oxford:Oxford University Press.
37. Jasanoff, S., 2006. Transparency in public sciences:purposes, reasons, limits. Law and Contemporary Problems, 69:22–45.
38. Juni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P., and Mattias, E., 2004. Risk of cardiovascular events and rofecoxib:cumulative meta-analysis. Lancet, 364:2021–2029.
39. Kaufmann, M., 2004. FDA official alleges pressure to suppress Vioxx findings. Washington Post, 8 October
40. Knight, F. H., 2006. “ Risk, Uncertainty and Profit ”. New york:Dover Publications.
41. Krumholz, H., Ross, J., Presler, A., and Egilman, D., 2007. What have we learned from Vioxx?. British Medical Journal, 334:120–123.
42. Latour, B., 2004. Why has critique run out of steam? From matter of fact to matter of concern. Critical Inquiry, 30:225–248.
43. Levidow, L., 2001. Precautionary uncertainty:regulating GM crops in Europe. Social Studies of Science, 31:842–874.
44. Lueck, T. J., 1982. At Lilly, the side-effects of Oraflex. New York Times, 15 August
45. Lynch, M., 1998. The discursive production of uncertainty:the OJ Simpson ‘dream team’ and the sociology of knowledge machine. Social Studies of Science, 28:829–868.
46. Mansfield, B., and Haas, J., 2006. Scale framing of scientific uncertainty in controversy over the endangered Steller Sea Lion. Environmental Politics, 15:78–94.
47. Massumi, B., 2007. Potential politics and the primacy of pre-emption. Theory and Event, 2 Available at:http://muse.jhu.edu/Journals/theory_and_event/v010/10.2massumi.html
48. Mathews, A. W., and Martinez, B., 2004. E-mails suggest Merck knew Vioxx's dangers at early stage. Wall Street Journal, 1 November:A1
49. McGoey, L., 2007. On the will to ignorance in bureaucracy. Economy and Society, 36:212–235.
50. McGoey, L., and Jackson, E., 2009. Seroxat and the suppression of clinical trial data:regulatory failure and the uses of legal ambiguity. Journal of Medical Ethics, 36:107–112.
51. Medawar, C., and Hardon, A., 2004. Medicines Out of Control? Antidepressants and the Conspiracy of Goodwill, Amsterdam:Aksant Academic Publishers.
52. Michaels, D., 2005. Doubt is their product:industry groups are fighting government regulation by fomenting scientific uncertainty. Scientific American, June:96–101.
53. Michaels, D., 2006a. Foreword:Sarbanes-Oxley for science. Law and Contemporary Problems, 69:1–19.
54. Michaels, D., 2006b. Manufactured uncertainty:protecting public health in the age of contested science and product defence. Annals of the New York Academy of Science, 1076:149–162.
55. Michaels, D., 2008. Doubt is Their Product:How Industry's Assault on Science Threatens Your Health, Oxford:Oxford University Press.
56. Murphy, M., 2004. Uncertain exposure and the privilege of imperception:activist scientists and race at the US Environmental Agency. Osiris, 19:266–282.
57. Murphy, M., 2006. Sick Building Syndrome and the Problem of Uncertainty, Durham, NC:Duke University Press.
58. Petryna, A., 2002. “ Life Exposed:biological citizens after Chernobyl ”. Princeton:Princeton University Press.
59. Power, M., 2004. The Risk Management of Everything:Rethinking the Politics of Uncertainty, London:Demos.
60. Power, M., 2007. Organized Uncertainty:Designing a World of Risk Management, Oxford:Oxford University Press.
61. Proctor, R., 1995. Cancer Wars:How Politics shapes what we Know and Don't Know about Cancer, New York:HarperCollins.
62. Proctor, R., 2006. ‘Everyone knew but no one had proof.’ Tobacco industry use of medical history expertise in US courts, 1990–2002. Tobacco Control, 15:iv117–iv125.
63. Rancière, J., 2004. The Philosopher and His Poor, Durham, NC:Duke University Press.
64. Tansey, B., 2007. Merck offers $4.5 billion to settle most Vioxx lawsuits. San Francisco Chronicle, 10 November
65. Thrift, N., 2005. Knowing Capitalism, London:Sage Publications.
66. Topol, E., 2004. Failing the public health—rofecoxib, Merck, and the FDA. New England Journal of Medicine, 351:1707–1709.
67. Waxman, H., 2005. The lessons of Vioxx—drug safety and sales. New England Journal of Medicine, 352:2576–2578.
68. Wynne, B., 1996. “ May the sheep safely graze? A reflexive view of the expert–lay knowledge divide ”. In Risk, Environment and Modernity:Towards a New Ecology, Edited by:Lash, S., Szerszynski, B., and Wynne, B., London:Sage.
69. Zaloom, C., 2004. The productive life of risk. Cultural Anthropology, 19:363–391.